AlzeCure Pharma AB (publ)

Stockholm Stock Exchange ALZCUR.ST

AlzeCure Pharma AB (publ) Price to Earnings Ratio (P/E) on January 14, 2025: -2.66

AlzeCure Pharma AB (publ) Price to Earnings Ratio (P/E) is -2.66 on January 14, 2025, a 54.72% change year over year. Price to earnings ratio compares the stock price to earnings per share; higher P/E suggests expectations for future earnings growth.
  • AlzeCure Pharma AB (publ) 52-week high Price to Earnings Ratio (P/E) is -2.16 on November 21, 2024, which is 18.87% above the current Price to Earnings Ratio (P/E).
  • AlzeCure Pharma AB (publ) 52-week low Price to Earnings Ratio (P/E) is -5.99 on March 01, 2024, which is -125.26% below the current Price to Earnings Ratio (P/E).
  • AlzeCure Pharma AB (publ) average Price to Earnings Ratio (P/E) for the last 52 weeks is -3.61.
Key data
Date Price to Earnings Ratio (P/E) Price to Sales Ratio (P/S) Price to Book Ratio (P/B) Dividend Yield
Market news
Loading...
Stockholm Stock Exchange: ALZCUR.ST

AlzeCure Pharma AB (publ)

CEO Mr. Martin Jönsson
IPO Date Nov. 28, 2018
Location Sweden
Headquarters HAelsovAegen 7
Employees 11
Sector Health Care
Industries
Description

AlzeCure Pharma AB (publ), a pharmaceutical company, develops drug therapies for the treatment of severe diseases and conditions that affect the central nervous system. The company is developing drug candidates based on the NeuroRestore, Alzstatin, and Painless research platforms. Its pipeline drug candidates include ACD856, which is in phase I clinical trial for Alzheimer's disease, sleep disorders, traumatic brain injuries, and Parkinson's disease; ACD857, ACD679, and ACD680 for Alzheimer's disease; ACD440, a TRPV1 antagonist that has completed phase I clinical trial for neuropathic pain; and TrkA-NAM for osteoarthritic pain. The company was founded in 2012 and is based in Huddinge, Sweden.

StockViz Staff

January 15, 2025

Any question? Send us an email